Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts.
galectin-1
multiple myeloma
osteoclasts
osteolytic disease
tumour microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Feb 2019
23 Feb 2019
Historique:
received:
23
12
2018
revised:
15
02
2019
accepted:
17
02
2019
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
1
3
2019
Statut:
epublish
Résumé
Multiple myeloma osteolytic disease is caused by an uncoupled bone-remodelling process with an increased osteoclast activity. Disease development relies on interactions between myeloma cells and bone marrow stromal cells. Recent findings suggest a role for glycan-binding proteins in myeloma microenvironment. Here, we investigated lectins involved in osteoclastogenesis and their role in myeloma bone disease. Microarray data analysis showed a lower expression of galectin-1 (gal-1) in mature osteoclasts compared to monocytic progenitor cells, confirmed at the RNA and protein levels in osteoclast cultures. Confocal microscopy showed that gal-1 localised predominantly in the sealing zone of mature osteoclasts. Although equal differentiated-osteoclast numbers, gal-1
Identifiants
pubmed: 30813402
pii: cancers11020261
doi: 10.3390/cancers11020261
pmc: PMC6406775
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Stichting Tegen Kanker
ID : NA
Organisme : Fonds De La Recherche Scientifique - FNRS
ID : NA
Organisme : Université de Liège
ID : NA
Références
Blood. 1999 Mar 1;93(5):1697-706
pubmed: 10029599
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Chem Rev. 1996 Mar 28;96(2):683-720
pubmed: 11848770
Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93
pubmed: 12223276
Biochem Biophys Res Commun. 2003 Oct 24;310(3):1010-6
pubmed: 14550305
Blood. 2004 Oct 15;104(8):2484-91
pubmed: 15187021
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Glycobiology. 2006 Nov;16(11):137R-157R
pubmed: 16840800
Cell. 2006 Sep 8;126(5):855-67
pubmed: 16959566
Dev Dyn. 2007 Apr;236(4):1014-24
pubmed: 17366633
J Bone Miner Res. 2007 Aug;22(8):1197-207
pubmed: 17488199
J Bone Miner Res. 2010 Mar;25(3):617-26
pubmed: 19888832
Cancer Res. 2010 Aug 1;70(15):6216-24
pubmed: 20647324
Cell Biol Int. 2011 Jun;35(6):579-86
pubmed: 21080908
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Mol Hum Reprod. 2011 Dec;17(12):747-57
pubmed: 21831883
BMC Res Notes. 2011 Oct 14;4:410
pubmed: 21996334
Glycobiology. 2013 Mar;23(3):363-80
pubmed: 23118208
Oncotarget. 2012 Nov;3(11):1335-47
pubmed: 23154454
Cancers (Basel). 2010 Apr 20;2(2):592-610
pubmed: 23658855
Curr Opin Hematol. 2013 Jul;20(4):327-35
pubmed: 23695449
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11451-6
pubmed: 23798433
Mol Endocrinol. 2014 Apr;28(4):546-53
pubmed: 24606124
J Biol Chem. 2014 Aug 29;289(35):24366-73
pubmed: 25023277
PLoS One. 2014 Sep 26;9(9):e107988
pubmed: 25259711
J Bone Miner Res. 2015 Jul;30(7):1268-79
pubmed: 25588731
Biochim Biophys Acta. 2015 Apr;1855(2):235-47
pubmed: 25819524
J Clin Invest. 2015 Jun;125(6):2279-92
pubmed: 25915583
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Cell Adh Migr. 2016 Mar 3;10(1-2):28-38
pubmed: 26418280
Oncotarget. 2016 May 24;7(21):30712-29
pubmed: 27095574
Leukemia. 2016 Dec;30(12):2351-2363
pubmed: 27311934
Blood. 2016 Sep 22;128(12):1590-603
pubmed: 27418644
Int J Mol Sci. 2016 Sep 16;17(9):
pubmed: 27649167
Mol Cancer. 2017 Feb 28;16(1):49
pubmed: 28241871
Leukemia. 2017 Nov;31(11):2426-2434
pubmed: 28344315
Leuk Lymphoma. 2018 Jan;59(1):14-28
pubmed: 28573897
Bone. 2017 Dec;105:35-41
pubmed: 28822790
J Biochem. 2018 Jan 1;163(1):39-50
pubmed: 28992109
Int J Mol Sci. 2017 Nov 21;18(11):null
pubmed: 29160796
Development. 1993 Dec;119(4):1229-36
pubmed: 8306885
Eur J Biochem. 1997 Feb 1;243(3):543-76
pubmed: 9057819